Tests dissolving magnesium clips during surgery for soft tissue sarcoma
Tests dissolving magnesium clips at the edges of removed tumors in adults with sarcoma.
Plain-language title generated from the registry record
Registry title: Safety and Efficacy of Degradable Magnesium Metal Clips in Surgical Margins of Radical Surgery for Malignant Bone and Soft Tissue Tumors
Key facts
- Where
- Guangzhou, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT06550765, who can take part
Where in China
- Guangdong Provincial People's HospitalGuangzhou, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Guangdong Provincial People's Hospital
- Trial code
- NCT06550765
- Record updated
- 13 August 2024
- Original description
To verify and evaluate the safety and efficacy of biodegradable magnesium metal clips in the surgical margins of radical surgery for bone and soft tissue malignant tumors.Read full original descriptionShow less
Safety and Efficacy of Degradable Magnesium Metal Clips in Surgical Margins of Radical Surgery for Malignant Bone and Soft Tissue Tumors: A Single-Center, Randomized Controlled Study
To verify and evaluate the safety and efficacy of biodegradable magnesium metal clips in the surgical margins of radical surgery for bone and soft tissue malignant tumors.
Inclusion: Participants must be of either gender, aged between 18 and 65 years; Diagnosis must be confirmed pathologically as osteosarcoma, synovial sarcoma, liposarcoma, or other bone and soft tissue sarcomas; Must have undergone standard chemotherapy and require en bloc resection; Participants must voluntarily enroll and sign an informed consent form; willing to closely cooperate with the physician to comply with all study requirements, including participation in all follow-up and assessments.
Exclusion: History of autoimmune disease, HIV infection, history of immunosuppressive disorder, or currently taking immunosuppressive drugs; Participation in any other clinical study currently or within 3 months prior to the screening visit; Severe dysfunction of the heart, liver, kidney, lung, or brain; History of syphilis (Treponema pallidum), active infection with hepatitis B or C, and positive for verified antigens; Patients have any other conditions that the researcher deems unsuitable for the study. Age is between 18 to 75 years old; Pregnant women or women who are breastfeeding.